NanoLogix, Inc. (NNLX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoLogix, Inc. (NNLX) with AI Score 47/100 (Weak). NanoLogix, Inc. is a biotechnology company specializing in rapid diagnostics test kits for detecting viable bacteria and microorganisms. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026NanoLogix, Inc. (NNLX) Healthcare & Pipeline Overview
NanoLogix, Inc. is a biotechnology company focused on live cell and rapid diagnostics, providing solutions for detecting viable bacteria and microorganisms across medical, defense, and industrial sectors. Their BioNanoPore kit and FlatPack Petri Plates cater to a diverse range of testing applications, positioning them within the broader biotechnology landscape.
Investment Thesis
NanoLogix operates in the biotechnology sector, specifically focusing on rapid diagnostics. The company's negative profit margin of -3631.2% and gross margin of -1994.6% indicate significant challenges in achieving profitability. While the company's products, such as the BioNanoPore kit and FlatPack Petri Plates, cater to a diverse range of sectors, including medical and defense, the lack of dividend yield suggests that investors are not currently receiving direct returns. Key value drivers would include successful commercialization of their diagnostic kits and expansion into new markets. Upcoming catalysts could include positive results from ongoing research and development efforts, or strategic partnerships that enhance market reach. However, the high beta of -34.75 indicates extreme volatility, and the company's financial performance needs to improve significantly to justify investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity and higher risk.
- P/E Ratio of -0.01 reflects the company's lack of profitability, as earnings are negative.
- Profit Margin of -3631.2% demonstrates significant operational inefficiencies and high costs relative to revenue.
- Gross Margin of -1994.6% suggests that the company is selling its products at a loss, indicating unsustainable pricing or high production costs.
- Beta of -34.75 indicates an inverse correlation with the market, but the magnitude suggests data anomalies or inaccuracies.
Competitors & Peers
Strengths
- Proprietary BioNanoPore technology.
- Rapid diagnostics capabilities.
- Diverse application across multiple sectors.
- Established customer base in medical and scientific entities.
Weaknesses
- Negative profit and gross margins.
- Limited market capitalization.
- High beta indicating extreme volatility.
- Dependence on a limited number of products.
Catalysts
- Upcoming: Potential strategic partnerships with pharmaceutical companies to expand market reach.
- Upcoming: Development and launch of new diagnostic tests for emerging infectious diseases.
- Ongoing: Research and development efforts focused on improving the BioNanoPore technology.
- Ongoing: Efforts to secure regulatory approvals for new products and applications.
- Ongoing: Expansion into point-of-care diagnostics market.
Risks
- Potential: Intense competition from larger and more established biotechnology companies.
- Potential: Regulatory hurdles and delays in obtaining approvals for new products.
- Ongoing: Negative profit and gross margins indicating financial instability.
- Potential: Technological obsolescence and the emergence of competing technologies.
- Ongoing: Limited market capitalization and liquidity on the OTC market.
Growth Opportunities
- Expansion into Point-of-Care Diagnostics: The point-of-care diagnostics market is experiencing rapid growth, driven by the demand for faster and more convenient testing solutions. NanoLogix can capitalize on this trend by developing portable and easy-to-use diagnostic kits that can be deployed in various settings, such as clinics, hospitals, and even homes. This expansion would require investment in miniaturization and user-friendly design, but it could significantly increase the company's market reach and revenue potential. The global point-of-care diagnostics market is projected to reach $40 billion by 2028.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies can provide NanoLogix with access to new markets and resources. By partnering with companies that are developing new drugs or therapies, NanoLogix can offer companion diagnostics that help identify patients who are most likely to benefit from these treatments. This would not only generate revenue for NanoLogix but also enhance its reputation as a provider of innovative diagnostic solutions. These partnerships could involve joint development agreements, licensing agreements, or co-marketing arrangements.
- Development of New Diagnostic Tests for Emerging Infectious Diseases: The emergence of new infectious diseases poses a significant threat to global health. NanoLogix can play a crucial role in combating these threats by developing rapid diagnostic tests that can quickly identify these diseases. This would require ongoing research and development efforts, as well as close collaboration with public health agencies and research institutions. The market for infectious disease diagnostics is expected to grow significantly in the coming years, driven by the increasing prevalence of these diseases and the need for faster and more accurate detection.
- Geographic Expansion into Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid growth in their healthcare sectors. NanoLogix can capitalize on this growth by expanding its presence in these markets. This would require adapting its products and marketing strategies to meet the specific needs of these markets. It would also require establishing partnerships with local distributors and healthcare providers. The healthcare market in emerging markets is expected to grow significantly in the coming years, driven by increasing incomes and aging populations.
- Leveraging BioNanoPore Technology for New Applications: The BioNanoPore technology has the potential to be used in a wide range of applications beyond diagnostics. NanoLogix can explore new applications for this technology, such as drug delivery, environmental monitoring, and industrial process control. This would require further research and development efforts, as well as collaboration with experts in these fields. By expanding the applications of its core technology, NanoLogix can diversify its revenue streams and reduce its reliance on the diagnostics market.
Opportunities
- Expansion into point-of-care diagnostics.
- Strategic partnerships with pharmaceutical companies.
- Development of new diagnostic tests for emerging infectious diseases.
- Geographic expansion into emerging markets.
Threats
- Intense competition in the biotechnology industry.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary BioNanoPore technology offers a unique approach to diagnostics.
- Specialized FlatPack Petri Plates cater to specific microorganism cultivation needs.
- Focus on rapid diagnostics provides a competitive edge in time-sensitive applications.
About NNLX
NanoLogix, Inc., based in Hubbard, Ohio, is a biotechnology company dedicated to developing and commercializing rapid diagnostics test kits. Founded with the goal of providing faster and more accurate detection of viable bacteria and other microorganisms, the company has focused on creating innovative solutions for various sectors, including medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing. NanoLogix's core product offerings include the BioNanoPore kit, which utilizes a water-permeable membrane to interact with organic and inorganic molecules, as well as proteins, and FlatPack Petri Plates, designed for the isolation and cultivation of diverse microorganisms under both aerobic and anaerobic conditions. These products are sold to established medical and scientific entities, such as laboratories, medical institutions, universities, businesses, and research establishments. The company's focus on rapid diagnostics addresses a critical need for timely and accurate detection in various applications, contributing to improved outcomes in healthcare, safety, and environmental monitoring. NanoLogix continues to refine its technologies and expand its product offerings to meet the evolving needs of its diverse customer base.
What They Do
- Develops live cell and rapid diagnostics test kits.
- Creates products that detect viable bacteria and other microorganisms.
- Offers the BioNanoPore kit, which uses a water-permeable membrane.
- Provides FlatPack Petri Plates for microorganism isolation and cultivation.
- Serves medical, national defense, and industrial sectors.
- Offers solutions for pharmaceutical, veterinary, and environmental testing.
Business Model
- Sells diagnostic test kits to laboratories and medical institutions.
- Generates revenue through direct sales to universities and research establishments.
- Focuses on providing rapid and accurate detection solutions.
Industry Context
NanoLogix operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory hurdles. The market for rapid diagnostics is growing, driven by the need for faster and more accurate detection of diseases and pathogens. Key trends include the development of point-of-care diagnostics and the increasing use of molecular diagnostics. NanoLogix competes with other biotechnology companies that offer similar diagnostic solutions. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong partnerships with key customers.
Key Customers
- Laboratories
- Medical Institutions
- Universities
- Research Establishments
- Businesses in various sectors
Financials
Chart & Info
NanoLogix, Inc. (NNLX) stock price: Price data unavailable
Latest News
No recent news available for NNLX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNLX.
Price Targets
Wall Street price target analysis for NNLX.
MoonshotScore
What does this score mean?
The MoonshotScore rates NNLX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Bret T. Barnhizer
CEO
Bret T. Barnhizer serves as the CEO of NanoLogix, Inc. His background includes experience in business development, strategic planning, and financial management within the biotechnology and healthcare sectors. He has a proven track record of leading companies through periods of growth and innovation. Barnhizer's expertise lies in identifying market opportunities, building strong teams, and securing funding for research and development initiatives. He also possesses strong leadership skills and a commitment to driving shareholder value.
Track Record: Under Bret T. Barnhizer's leadership, NanoLogix has focused on refining its core technologies and expanding its product offerings. Key milestones include the development of new diagnostic tests and the establishment of strategic partnerships. Barnhizer has also overseen efforts to improve the company's financial performance and secure additional funding. His strategic decisions have been instrumental in positioning NanoLogix for future growth.
NNLX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NanoLogix may not meet the minimum financial standards or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to adhere to the same listing standards as those on major exchanges like NYSE or NASDAQ, resulting in less transparency for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in NNLX.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Uncertainty regarding the company's long-term viability.
- Risk of delisting or suspension from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation for several years.
- Products are used in medical and scientific applications.
- Company has established relationships with customers in various sectors.
- CEO has relevant experience in the biotechnology industry.
- Company maintains a website and provides contact information.
Common Questions About NNLX
What does NanoLogix, Inc. do?
NanoLogix, Inc. is a biotechnology company that develops and commercializes rapid diagnostic test kits for detecting viable bacteria and other microorganisms. Their products, including the BioNanoPore kit and FlatPack Petri Plates, are used in various sectors such as medical, national defense, and industrial testing. The company's focus is on providing faster and more accurate detection solutions to established medical and scientific entities, including laboratories, medical institutions, universities, businesses, and research establishments.
What do analysts say about NNLX stock?
There is currently no available analyst coverage or consensus regarding NanoLogix (NNLX) stock, likely due to its micro-cap status and trading on the OTC market. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own independent research and consider the company's financial performance, growth opportunities, and risk factors before making any investment decisions. The lack of analyst coverage highlights the importance of thorough due diligence.
What are the main risks for NNLX?
The main risks for NanoLogix include its negative profit and gross margins, indicating financial instability. The company also faces intense competition in the biotechnology industry and regulatory hurdles in obtaining approvals for new products. Additionally, its limited market capitalization and liquidity on the OTC market pose challenges for investors. Technological obsolescence and the emergence of competing technologies also represent potential threats to the company's long-term viability. Investors should carefully consider these risks before investing in NNLX.
What are the key factors to evaluate for NNLX?
NanoLogix, Inc. (NNLX) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary BioNanoPore technology.. Primary risk to monitor: Potential: Intense competition from larger and more established biotechnology companies.. This is not financial advice.
How frequently does NNLX data refresh on this page?
NNLX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NNLX's recent stock price performance?
Recent price movement in NanoLogix, Inc. (NNLX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary BioNanoPore technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NNLX overvalued or undervalued right now?
Determining whether NanoLogix, Inc. (NNLX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NNLX?
Before investing in NanoLogix, Inc. (NNLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or unreliable.
- AI analysis is pending.